Overview

A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled Therapeutic Equivalence Study of Three Imiquimod Cream 5% Treatments for Patients With Actinic Keratosis

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Bio-equivalence Study

Phase:

Phase 3

Details

Lead Sponsor:

Apotex Inc.

Treatments:

Imiquimod